FDA says AstraZeneca's vandetanib has "substantial toxicity" risks

11/30/2010 | Google

FDA staff cited "substantial toxicity" risks associated with vandetanib, AstraZeneca's experimental drug for medullary thyroid cancer. About 31% of patients who received the treatment in a study experienced adverse effects, compared with 13% of those given placebo, the reviewers said. The agency's report was issued ahead of a panel review of the medicine Thursday.

View Full Article in:

Google

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations